Boehringer Ingelheim's Phase III trials of survodutide, a glucagon/GLP-1 dual agonist, showed significant metabolic health improvements in people with obesity. The SYNCHRONIZE-1 trial reported up to 16.6% weight loss, 34% reduction in visceral fat, and 63% reduction in liver fat over 76 weeks, with minimal lean mass loss. The SYNCHRONIZE-MASLD trial showed liver fat normalization in 60% of participants with metabolic liver disease after 48 weeks. These results highlight survodutide's potential to target harmful fat and improve metabolic conditions linked to obesity, with further studies ongoing.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Hi-View Resources Inc. has started its 2026 exploration program in the Toodoggone Mining District, British Columbia, focusing on porphyry targets at key sites like Lawyer’s East, Borealis, and Golden Stranger. The program includes 50 line kilometres ...
The U.S. Patent and Trademark Office (USPTO) has introduced an AI-assisted image search feature in its public trademark search system, TM Search, using technology from Clarivate Plc. This new tool allows users to upload images and compare them agains...
AIB Data Centers Inc. is considered a speculative buy with a $3.50 price target based on its 65 MW energized capacity. The investment case depends heavily on securing a single anchor lease at its CLT-01 facility, which would validate its business mod...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
